A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, retrospective cohort analysis comparing 321 CL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Mato, Anthony R., Roeker, Lindsey E., Eyre, Toby A., Nabhan, Chadi, Lamanna, Nicole, Hill, Brian T., Brander, Danielle M., Barr, Paul M., Lansigan, Frederick, Cheson, Bruce D., Singavi, Arun K., Yazdy, Maryam Sarraf, Shah, Nirav N., Allan, John N., Bhavsar, Erica B., Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen J., Williams, AnnaLynn M., Skarbnik, Alan P., Goy, Andre H., Goodfriend, Julie M., Dorsey, Colleen, Coombs, Catherine C., Tuncer, Hande, Ujjani, Chaitra S., Jacobs, Ryan, Winter, Allison M., Pagel, John M., Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Zelenetz, Andrew, Kirkwood, Amy A., Fox, Christopher P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538868/
https://ncbi.nlm.nih.gov/pubmed/31101647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000180
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados